NCT06894771
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06894771
Title A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)
Acronym MK-4700-001
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Merck Sharp & Dohme LLC
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ISR | CAN

Facility Status City State Zip Country Details
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0301) Hackensack New Jersey 07601 United States Details
NEXT Oncology ( Site 0300) San Antonio Texas 78229 United States Details
Princess Margaret Cancer Center ( Site 0101) Toronto Ontario M5G 2M9 Canada Details
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0102) Québec Quebec G1J 1Z4 Canada Details
Rambam Health Care Campus ( Site 0201) Haifa 3109601 Israel Details
Rabin Medical Center ( Site 0202) Petah Tikva 4941492 Israel Details
Sheba Medical Center ( Site 0200) Ramat Gan 5265601 Israel Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field